Similarities and differences in early retinal phenotypes in hypertension and diabetes

Journal of Hypertension

Volumn 29, Issue 9, 2011, Pages 1667-1675

  Grosso, Andrea ^a   Cheung, Ning ^b   Veglio, Franco ^c   Wong, Tien Yin ^b,d  

^a Ophthalmic Private Practice   (Italy)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MOLINETTE HOSPITAL   (Italy)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

diabetes; hypertension; microvascular complications; retinal microvascular signs; retinopathy

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; INSULIN; VASCULOTROPIN;

AFRICAN AMERICAN; AGE; APOPTOSIS; BLOOD FLOWMETRY; BLOOD PRESSURE REGULATION; BLOOD RETINA BARRIER; BLOOD VESSEL DIAMETER; CARDIOVASCULAR AUTOREGULATION; CARDIOVASCULAR RISK; CAUCASIAN; CELL DAMAGE; CELL DIVISION; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DOPPLER FLOWMETRY; ENDOTHELIAL DYSFUNCTION; ETHNIC DIFFERENCE; EXTRACELLULAR MATRIX; EXUDATIVE MACULAR DEGENERATION; GLIA CELL; GLYCEMIC CONTROL; HISTONE MODIFICATION; HUMAN; HYPERTENSION RETINOPATHY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MEAN ARTERIAL PRESSURE; MEDICAL PHOTOGRAPHY; MICROANEURYSM; MUELLER CELL; NEOVASCULARIZATION (PATHOLOGY); NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL TOMOGRAPHY; PATHOGENESIS; PATIENT IDENTIFICATION; PHENOTYPE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RETINA BLOOD FLOW; RETINA BLOOD VESSEL; RETINA DISEASE; RETINA EXAMINATION; RETINA HEMORRHAGE; RETINA ISCHEMIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MICROANEURYSM; RETINAL FLOWMETRY; RETINAL TOMOGRAPHY; REVIEW; RISK REDUCTION; STRESS; TEAMWORK; VISUAL IMPAIRMENT;

EID: 80051933364     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283496655     Document Type: Review

References (96)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension. Analysis of worldwide data. Lancet 2005; 365:217-223. (Pubitemid 40138015)
2. Wild SH, Forouhi NG. What is the scale of the future diabetes epidemic, and how certain are we about it? Diabetologia 2007; 50:903-905. (Pubitemid 46559269)
3. Asplund K, Karvanen J, Giampaoli S, Jousilahti P, Niemela M, Broda G, et al. Relative risks for stroke by age, sex, and population based on follow-up of 18 European populations in the morgam project. Stroke 2009; 40:2319-2326.
4. Wong TY, Mitchell P. Hypertensive retinopathy. New Engl J Med 2004; 351:2310-2317. (Pubitemid 39552747)
5. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010; 376:124-136.
6. Grosso A, Veglio F, Porta M, Grignolo FM, Wong TY. Hypertensive retinopathy revisited: some answers, more questions. Br J Ophthalmol 2005; 89:1646-1654. (Pubitemid 41729914)
7. Cunha-Vaz J, Bernardes R. Nonproliferative retinopathy in diabetes type 2. Initial stages and characterization of phenotypes. Prog Retin Eye Res 2005; 24:355-377. (Pubitemid 40238669)
8. Nguyen TT, Kawasaki R, Kreis AJ, Wang JJ, Shaw J, Vilser W, Wong TY. Correlation of light-flicker-induced retinal vasodilation and retinal vascular caliber measurements in diabetes. Invest Ophthalmol Vis Sci 2009; 50:5609-5613.
9. Delles C, Michelson G, Harazny J, Oehmer S, Hilgers KF, Schmieder RE. Impaired endothelial function of the retinal vasculature in hypertensive patients. Stroke 2004; 35:1289-1293. (Pubitemid 38697445)
10. Nguyen TT, Kawasaki R, Wang JJ, Kreis AJ, Shaw J, Vilser W, Wong TY. Flicker light-induced retinal vasodilation in diabetes and diabetic retinopathy. Diabetes Care 2009; 32:2075-2080.
11. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcirculation in hypertension: a new target for treatment? Circulation 2001; 104:735-740.
12. Varma R. Diabetic retinopathy: challenges and future directions. Am J Ophthalmol 2006; 141:539-541. (Pubitemid 43265961)
13. Kralev S, Zimmerer E, Buchholz P, Lin J, Economopoulou M, Lang S, et al. Microvascular retinal changes in patients presenting with acute coronary syndromes. Microvasc Res 2010; 79:150-153.
14. Houben AJ, Stehouwer CD. Retinal microvascular abnormalities: can they predict future risk of hypertension? J Hypertens 2009; 27:2346-2348.
15. Klein R, Klein BE, Moss SE, Wong TY. The relationship of retinopathy in persons without diabetes to the 15-year incidence of diabetes and hypertension. Beaver Dam Eye Study. Trans Am Ophtalmol Soc 2006; 104:98-107.
16. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007; 356:830-840.
17. Wong TY, Klein R, Amirul Islam FM, Cotch MF, Couper DJ, Klein BE, et al. Three-year incidence and cumulative prevalence of retinopathy: the atherosclerosis risk in communities study. Am J Ophthalmol 2007; 143:970-976. (Pubitemid 46764650)
18. Ikram MK, Witteman JC, Vingerling JR, Breteler MM, Hofman A, de Jong PT. Retinal vessel diameters and risk of hypertension: The Rotterdam Study. Hypertension 2006; 47:189-194. (Pubitemid 43189762)
19. Baker ML, Wang JJ, Liew G, Hand PJ, De Silva DA, Lindley RI, et al. Differential associations of cortical and subcortical cerebral atrophy with retinal vascular signs in patients with acute stroke. Stroke 41:2143-2150.
20. Cheung N, Mosley T, Islam A, Kawasaki R, Sharrett AR, Klein R, et al. Retinal microvascular abnormalities and subclinical magnetic resonance imaging brain infarct: a prospective study. Brain 2010; 133:1987-1993.
21. Wong TY, Mohamed Q, Klein R, Couper DJ. Do retinopathy signs in nondiabetic individuals predict the subsequent risk of diabetes? Br J Ophthalmol 2006; 90:301-303. (Pubitemid 43325459)
22. Nguyen TT, Wong TY. Retinal vascular manifestations of metabolic disorders. Trends Endocrinol Metab 2006; 17:262-268. (Pubitemid 44287473)
23. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 2011; 34:145-150.
24. Cheung N, Wong TY. Diabetic retinopathy and systemic vascular complications. Prog Retin Eye Res 2008; 27:161-176.
25. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110:1677-1682. (Pubitemid 37025422)
26. Klein R, Klein BEK, Moss SE. The relation of systemic hypertension to changes in the retinal vasculature: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 1997; 95:329-348.
27. Wong TY, Klein R, Islam FM, CotchMF, Folsom AR, Klein BE, et al. Diabetic retinopathy in a multiethnic cohort in the united states. Am J Ophthalmol 2006; 141:446-455.
28. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The wisconsin epidemiologic study of diabetic retinopathy. Xiv. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994; 112:1217-1228. (Pubitemid 24360961)
29. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (ukpds 36): prospective observational study. BMJ 2000; 321:412-419. (Pubitemid 30609443)
30. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR. Ukpds 50: risk factors for incidence and progression of retinopathy in type ii diabetes over 6 years from diagnosis. Diabetologia 2001; 44:156-163. (Pubitemid 32156199)
31. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension task force document. J Hypertens 2009; 27:2121-2158.
32. Volpe M, Tocci G. 2007 ESH/ESC guidelines for the management of hypertension, from theory to practice. Global cardiovascular risk concept. J Hypertens Suppl 2009; 27:S3-S11.
33. Wong TY, Klein R, Klein BE, Tielsch JM, Hubbard L, Nieto FJ. Retinal microvascular abnormalities and their relationship with hypertension, cardiovascular disease, and mortality. Surv Ophthalmol 2001; 46:59-80. (Pubitemid 32781831)
34. Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, Nickerson RS, Dawber TR. The framingham eye study. I. Outline and major prevalence findings. Am J Epidemiol 1977; 106:17-32. (Pubitemid 8160455)
35. Sharp PS, Chaturvedi N, Wormald R, McKeigue PM, Marmot MG, Young SM. Hypertensive retinopathy in afro-caribbeans and europeans. Prevalence and risk factor relationships. Hypertension 1995; 25:1322-1325.
36. Wong TY, Klein R, Duncan BB, Nieto FJ, Klein BE, Couper DJ, et al. Racial differences in the prevalence of hypertensive retinopathy. Hypertension 2003; 41:1086-1091. (Pubitemid 36548607)
37. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102:527-532. (Pubitemid 14127839)
38. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102:520-526. (Pubitemid 14127838)
39. Peng XY, Wang FH, Liang YB, Wang JJ, Sun LP, Peng Y, et al. Retinopathy in persons without diabetes: The Handan Eye Study. Opthalmology 117:531-537.
40. Jeganathan VS, Cheung N, Tay WT, Wang JJ, Mitchell P, Wong TY. Prevalence and risk factors of retinopathy in an Asian population without diabetes: The Singapore Malay Eye Study. Arch Opthalmol 128:40-45.
41. Wong T, Mitchell P. The eye in hypertension. Lancet 2007; 369:425-435. (Pubitemid 46188480)
42. Grosso A. Detection and management of vascular hypertension. Compr Ophthalmol Update 2007; 8:145-151; discussion 153-154. (Pubitemid 47204920)
43. Chao JR, Lai MY, Azen SP, Klein R, Varma R. Retinopathy in persons without diabetes: The Los Angeles Latino Eye Study. Invest Ophthalmol Vis Sci 2007; 48:4019-4025. (Pubitemid 351261024)
44. Venkatramani J, Mitchell P. Ocular and systemic causes of retinopathy in patients without diabetes mellitus. BMJ 2004; 328:625-629. (Pubitemid 38340034)
45. Cheung N, Wong TY. Obesity and eye diseases. Surv Ophthalmol 2007; 52:180-195. (Pubitemid 46371493)
46. Tso MO, Jampol LM. Pathophysiology of hypertensive retinopathy. Ophthalmology 1982; 89:1132-1145. (Pubitemid 12003230)
47. Buchi ER, Kurosawa A, Tso MO. Retinopathy in diabetic hypertensive monkeys: a pathologic study. Graefes Arch Clin Exp Ophthalmol 1996; 234:388-398. (Pubitemid 26150822)
48. Hayreh SS. Classification of hypertensive fundus changes and their order of appearance. Ophthalmologica 1989; 198:247-260. (Pubitemid 19143852)
49. McLeod D. Why cotton wool spots should not be regarded as retinal nerve fibre layer infarcts. Br J Ophthalmol 2005; 89:229-237. (Pubitemid 40175224)
50. Kristinsson JK, Gottfredsdottir MS, Stefansson E. Retinal vessel dilatation and elongation precedes diabetic macular oedema. Br J Ophthalmol 1997; 81:274-278. (Pubitemid 27196755)
51. Gottfredsdottir MS, Stefansson E, Jonasson F, Gislason I. Retinal vasoconstriction after laser treatment for diabetic macular edema. Am J Ophthalmol 1993; 115:64-67. (Pubitemid 23019040)
52. Klein R, Meuer SM, Moss SE, Klein BE. Retinal microaneurysm counts and 10-year progression of diabetic retinopathy. Arch Ophthalmol 1995; 113:1386-1391.
53. Kohner EM, Stratton IM, Aldington SJ, Turner RC, Matthews DR. Microaneurysms in the development of diabetic retinopathy (ukpds 42). Uk prospective diabetes study group. Diabetologia 1999; 42:1107-1112. (Pubitemid 29408809)
54. Frank RN. The galactosemic dog. A valid model for both early and late stages of diabetic retinopathy. Arch Ophthalmol 1995; 113:275-276.
55. Kern TS, Engerman RL. A mouse model of diabetic retinopathy. Arch Ophthalmol 1996; 114:986-990. (Pubitemid 26271465)
56. Holman RR, Sanjoy KP, Bethel A, Matthews D, Neil AW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589.
57. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006; 55:2401-2411. (Pubitemid 44871140)
58. Meyer-Rusenberg B, Pavlidis M, Stupp T, Thanos S. Pathological changes in human retinal ganglion cells associated with diabetic and hypertensive retinopathy. Graefes Arch Clin Exp Ophthalmol 2007; 245:1009-1018.
59. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998; 102:783-791. (Pubitemid 28399611)
60. Lieth E, LaNoue KF, Antonetti DA, Ratz M. Diabetes reduces glutamate oxidation and glutamine synthesis in the retina. The penn state retina research group. Exp Eye Res 2000; 70:723-730.
61. Lim LS, Tai ES, Mitchell P, Wang JJ, Tay WT, Lamoureux E, Wong TY. C-reactive protein, body mass index, and diabetic retinopathy. Invest Ophthalmol Vis Sci 51:4458-4463.
62. Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW, Levison SW. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005; 54:1559-1565. (Pubitemid 40586690)
63. Fetler L, Amigorena S. Neuroscience. Brain under surveillance: the microglia patrol. Science 2005; 309:392-393. (Pubitemid 40994671)
64. de Venecia G, Jampol LM. The eye in accelerated hypertension. II. Localized serous detachments of the retina in patients. Arch Ophthalmol 1984; 102:68-73. (Pubitemid 14220009)
65. Leishman R. The retinal vessels in hypertensive disease. Proc R Soc Med 1952; 45:419-426.
66. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002; 47:S253-262. (Pubitemid 36351245)
67. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004; 18:1450-1452. (Pubitemid 39561611)
68. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 2002; 86:363-365. (Pubitemid 34293277)
69. Dahlof B, Herlitz H, Aurell M, Hansson L. Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system. Am J Hypertens 1992; 5:900-911. (Pubitemid 23022576)
70. Michelson G, Warntges S, Harazny J, Oehmer S, Delles C, Schmieder RE. Effect of nos inhibition on retinal arterial and capillary circulation in early arterial hypertension. Retina 2006; 26:437-444. (Pubitemid 44197637)
71. Bock KD. Regression of retinal vascular changes by antihypertensive therapy. Hypertension 1984; 6:III158-III162.
72. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987; 36:808-812. (Pubitemid 17145301)
73. Kowluru RA, Zhong Q, Kanwar M. Metabolic memory and diabetic retinopathy: role of inflammatory mediators in retinal pericytes. Exp Eye Res 2010; 90:617-623.
74. Roy S, Sala R, Cagliero E, Lorenzi M. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci USA 1990; 87:404-408.
75. White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, Davis MD, DCCT-EDIC Research Group. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes 2010; 59:1244-1253.
76. Zhong Q, Kowluru RA. Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes 2011; 60:1304-1313.
77. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al., DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008; 18:1385-1393.
78. Liew G, Mitchell P, Rochtchina E, Wong TY, Hsu W, Lee ML, et al. Fractal analysis of retinal microvasculature and coronary heart disease mortality. Eur Heart J 2011; 32:422-429.
79. Grosso A, Rabbia F, Fea A, Grosso T, Grignolo F, Veglio F. Comparison between generalized retinal arteriolar narrowing and left ventricular mass in young untreated hypertensive patients. Blood Press 2006; 15:308-312.
80. Hughes AD, Stanton AV, Jabbar AS, Chapman N, Martinez-Perez ME, Thoma SAM. Effect of antihypertensive treatment on retinal microvascular changes in hypertension. J Hypertens 2008; 26:1703-1707.
81. Thom S, Stettler C, Stanton A, Witt N, Tapp R, Chaturvedi N, et al. Differential effects of antihypertensive treatment on the retinal microcirculation. An Anglo-Scandinavian Cardiac Outcomes Trial Substudy. Hypertension 2009; 54:405-408.
82. Cooper ME, Tikellis C, Thomas MC. Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system. J Hypertens 2006; 24:S57-S63. (Pubitemid 44336825)
83. Nguyen TT, Wang JJ, Wong TY. Retinal vascular changes in prediabetes and prehypertension: new findings and their research and clinical implications. Diabetes Care 2007; 30:2708-2715.
84. Wong TY. Age-related macular degeneration and cardiovascular disease in the era of antivascular endothelial growth factor therapies. Am J Ophthalmol 2009; 148:327-329.
85. Wong TY. Age-related macular degeneration: why should stroke physicians care? Stroke 2010; 41:575-576.
86. Liew G, Wang JJ, Mitchell P, Wong TY. Retinal vascular imaging: a new tool in microvascular disease research. Circ Cardiovasc Imaging 2008; 2:156-161.
87. Rubino F, Kaplan LM, Schauer PR, Cummings DE, Diabetes Surgery Summit Delegates. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg 2010; 251:399-405.
88. Mineo D, Pileggi A, Alejandro R, Ricordi C. Point: steady progress and current challenges in clinical islet transplantation. Diabetes Care 2009; 32:1563-1569.
89. Meigs JB, Hu FB, Rifai N,Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004; 291:1978-1986. (Pubitemid 38544279)
90. Nagel E, Vilser W, Lanzl I. Age, blood pressure, and vessel diameter as factors influencing the arterial retinal flicker response. Invest Ophthalmol Vis Sci 2004; 45:1486-1492. (Pubitemid 38859329)
91. Dorner GT, Garhofer G, Kiss B, Polska E, Polak K, Riva CE, Schmetterer L. Nitric oxide regulates retinal vascular tone in humans. Am J Physiol Heart Circ Physiol 2003; 285:H631-H636. (Pubitemid 36885894)
92. Harazny JM, Raff U, Welzenbach J, Ott C, Ritt M, Lehmann M, et al. New software analyses increase the reliability of measurements of retinal arterioles morphology by scanning laser Doppler flowmetry in humans. J Hypertens 2011; 29:777-782.
93. Park JH, Woo SJ, Ha YJ, Yu HG. Effect of vitrectomy on macular microcirculation in patients with diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2009; 247:1009-1017.
94. Nagaoka T, Sato E, Takahashi A, Yokota H, Sogawa K, Yoshida A. Impaired retinal circulation in patients with type 2 diabetes mellitus: retinal laser Doppler velocimetry study. Invest Ophthalmol Vis Sci 2010; 51:6729-6734.
95. Riva CE, Falsini B. Functional laser Doppler flowmetry of the optic nerve: physiological aspects and clinical applications. Prog Brain Res 2008; 173:149-163.
96. Wang Y, Lu A, Gil-Flamer J, Tan O, Izatt JA, Huang D. Measurement of total blood flow in the normal human retina using Doppler Fourier-domain optical coherence tomography. Br J Ophthalmol 2009; 93:634-637.